Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

NCT03937635 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT03937635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03937635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Recruiting
Start date
September 16, 2019
Completion date
December 31, 2029
Enrollment
288 (estimated)
Sites
748

Conditions

As the registry lists them; a condition with its own page is linked.

smoldering plasma cell myeloma